<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-163184</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Positioning of sodium-glucose cotransporter-2 inhibitors in national and international guidelines</dc:title>
<dc:description xml:lang="en">Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) selectively and reversibly inhibit sodium-glucose cotransporter-2 (SGLT2), promoting renal glucose excretion and reducing plasma glycaemia. By increasing renal glucose excretion, these drugs favour a negative energy balance, leading to weight loss. Their glucoselowering effect is independent of insulin. Although these drugs have only recently been developed, they have been included in all the main national and international guidelines since 2014. The present review summarises the most important recommendations on the use of SGLT2 in patients with DM2 contained in the most recently published guidelines and consensus statements (AU)</dc:description>
<dc:creator>Morillas, Carlos</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los inhibidores del cotransportador sodio-glucosa tipo 2 (iSGLT2) inhiben al SGLT2 de forma selectiva y reversible, promoviendo la excrecion renal de glucosa y reduciendo la glucemia plasmatica. Al aumentar la excrecion renal de glucosa se favorece el balance energetico negativo y condiciona un efecto reductor del peso, y su efecto hipoglucemiante es independiente de la insulina. A pesar de que su aparicion es reciente, ya estan incluidos en todas las guias nacionales e internacionales relevantes desde 2014. En esta revision se repasan las recomendaciones mas importantes respecto al manejo de los iSGLT2 en pacientes con diabetes mellitus tipo 2 que figuran en las ultimas guias o consensos publicados (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);147(supl.esp.1): 49-53, nov. 2016. ilus</dc:source>
<dc:identifier>ibc-163184</dc:identifier>
<dc:title xml:lang="es">Posicionamiento en guías nacionales e internacionales de los inhibidores del cotransportador sodio-glucosa tipo 2</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d3946^s22057</dc:subject>
<dc:subject>^d6063^s22021</dc:subject>
<dc:subject>^d30291</dc:subject>
<dc:subject>^d11756</dc:subject>
<dc:subject>^d1812^s22021</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d50911^s22006</dc:subject>
<dc:subject>^d50911^s22073</dc:subject>
<dc:subject>^d24542</dc:subject>
<dc:subject>^d35176</dc:subject>
<dc:type>article</dc:type>
<dc:date>201611</dc:date>
</metadata>
</record>
</ibecs-document>
